Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sangamo Therapeutics
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, 18 years of age or older with documented HIV diagnosis.
Must be willing to comply with study-mandated evaluations; including discontinuation of current antiretroviral therapy during the treatment interruption.
Initiated HAART therapy within (≤) 1 year of HIV diagnosis or suspected infection.
Undetectable HIV-1 RNA for at least 2 months prior to screening and at screening.
CD4+ T-cell count ≥500 cells/µL.
Absolute neutrophil count (ANC) ≥ 2500/mm3.
Platelet count ≥ 200,000/mm3.
You may not be if
Acute or chronic hepatitis B or hepatitis C infection.
Active or recent (in prior 6 months) AIDS defining complication.
Any cancer or malignancy within the past 5 years, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin or low grade (0 or 1) anal or cervical dysplasia.
Current diagnosis of NYHA grade 3 or 4 CHF, uncontrolled angina or uncontrolled arrhythmias.
History or any features on physical examination indicative of a bleeding diathesis.
Received HIV experimental vaccine within 6 months prior to screening, or any previous gene therapy using an integrating vector.
Use of chronic corticosteroids, hydroxyurea, or immunomodulating agents within 30 days prior to screening.
Use of Aspirin, dipyridamole, warfarin or any other medication that is likely to affect platelet function or other aspects of blood coagulation during the 2 week period prior to leukapheresis.
Currently participating in another clinical trial or participation in such a trial within 30 days prior to screening visit.
Currently taking maraviroc or have received maraviroc within 6 months prior to screening.
Clareo Health | Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
